Strength of recommendation: Weak recommendation with
evidence coming from a single study involving participants with asthma
from 22 years of age.27
|
Other
considerations: Evidence comes from the use of combined corticosteroid
and long-acting bronchodilator inhalers for asthma but is likely to be
generalizable. If possible use the same inhaler system for all inhaled
medications for the same patient and if possible restrict to once daily. |
References: Axelsson27. |
Medication reminders, mobile applications and web-based
applications, monitors or routines can be recommended to improve
adherence, symptom control and quality of life (Grade B, Evidence level
I-IV) |
Medication reminders, mobile applications and web-based
applications, monitors or routines can be recommended to improve
adherence, symptom control and quality of life (Grade B, Evidence level
I-IV) |
Medication reminders, mobile applications and web-based
applications, monitors or routines can be recommended to improve
adherence, symptom control and quality of life (Grade B, Evidence level
I-IV) |
Strength of recommendation: Weak recommendation for
smartphone- based health applications, medication reminders or monitors
as only suggested by qualitative studies.35,36,38
Recommendation for the use of a specific web-application
(MyMediHealthApp) is moderate since efficacy proven by a controlled
trial.34
|
Other considerations: A smartphone-based personalized
health app, medication reminders or monitors were suggested in
qualitative studies.
All studies focused on asthma but likely to be also applicable to
allergy.
|
References: Naimi35,
Blaakman36, Koster38,
Johnson34.
|